Somewhat Favorable News Coverage Somewhat Unlikely to Impact Argos Therapeutics (ARGS) Share Price
News headlines about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Argos Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.2168194632634 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Argos Therapeutics (ARGS) traded down $0.02 during trading on Friday, hitting $1.58. The stock had a trading volume of 397,244 shares, compared to its average volume of 895,540. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. The company has a market cap of $6.92, a price-to-earnings ratio of -0.07 and a beta of 0.99. Argos Therapeutics has a 12-month low of $1.53 and a 12-month high of $106.00.
Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.00) EPS for the quarter.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.